Impairments to executive function in emerging adults with Huntington disease

Abstract

Background and objectivesThe clinical diagnosis of Huntington disease (HD) is typically made once motor symptoms and chorea are evident. Recent reports highlight the onset of cognitive and psychiatric symptoms before motor manifestations. These findings support further investigations of cognitive function across the lifespan of HD sufferers.MethodsTo assess cognitive symptoms in the developing brain, we administered assessments from the National Institutes of Health Toolbox Cognitive Battery, an age-appropriate cognitive assessment with population norms, to a cohort of children, adolescents and young adults with (gene-expanded; GE) and without (gene-not-expanded; GNE) the trinucleotide cytosine, adenine, guanine (CAG) expansion in the Huntingtin gene. These five assessments that focus on executive function are well validated and form a composite score, with population norms. We modelled these scores across age, and CAP score to estimate the slope of progression, comparing these results to motor symptoms.ResultsWe find significant deficits in the composite measure of executive function in GE compared with GNE participants. GE participant performance on working memory was significantly lower compared with GNE participants. Modelling these results over age suggests that these deficits occur as early as 18 years of age, long before motor manifestations of HD.ConclusionsThis work provides strong evidence that impairments in executive function occur as early as the second decade of life, well before anticipated motor onset. Future investigations should delineate whether these impairments in executive function are due to abnormalities in neurodevelopment or early sequelae of a neurodegenerative process.

Prodromal Cognitive Changes as a Prognostic Indicator of Forthcoming Huntington's Disease Severity: A Retrospective Longitudinal Study

“…Our study supports the evidence that cognitive changes might anticipate and predict motor progression in neurodegenerative diseases. Specifically, executive functions are documented to be impaired early in HD patients’ life 33 and are altered in several other neurological diseases. For example, SDMT does represent a critical measure in Multiple Sclerosis (MS) 34 and may predict gait impairment in this disease 35 .…”

Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease

“…[ 9 , 10 ] Higher numbers of CAG repeats are thought to be associated with an earlier onset of disease, a faster rate of clinical progression, and increasing disease severity. [ 11 ] Present studies show that disrupted neural circuit physiology could be found in HD mice during the first neonatal week [ 12 ] and cognitive impairments could happen earlier than the motor symptoms even in the second decades of patients, [ 13 , 14 ] which suggests the disease onset is the cumulative effect and the need for disease-modifying drugs of HD is urgent. Diagnosis of HD is typically based on clinical features, family history, and genetic testing to confirm the presence of the CAG repeat expansion in the HTT gene.…”

The Role of Innovation Technology in the Rehabilitation of Patients Affected by Huntington’s Disease: A Scoping Review

“…It encompasses various traditional approaches, including physical therapy, occupational therapy, speech therapy, and neuropsychology. However, the use of new rehabilitation technologies, such as virtual reality (VR), Pc-Based training, or innovative techniques, such as non-invasive brain stimulation (NIBS), could make a significant contribution to improving functional outcomes, as seen in other conditions [15][16][17][18].…”